Aseko dba Glytec has filed a notice of an exempt offering of securities to raise $10 Million in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Aseko dba Glytec is raising up to $10 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Aseko dba Glytec
Stopping Preventable Harm. Backed by Over 20 Years of Proven Outcomes. GlytecOne makes metabolic management safe and measurable. Hospitals use GlytecOne to standardize metabolic care, surface risk before it becomes harm, and prove measurable outcomes before CMS makes them public. Health Plans use GlytecOne to close the metabolic care gap for inpatient and post-discharge to close Stars and HEDIS measure gaps for health plan members. Since 2006, Glytec has been helping hospitals and hospital systems make glycemic care safer, more consistent, and easier to manage as a system-level responsibility. We provide clinical teams with current visibility and FDA-cleared insulin decision support so high-risk insulin care does not depend on manual calculations, workarounds, or variability from one unit or shift to the next. Glytec was founded on a straightforward belief: that hospitals should not have to manage high-alert insulin medications with manual protocols, singular dependencies on sliding-scale dosing, and unvalidated calculators. That approach was dangerous then. It is indefensible now. Over nearly two decades, Glytec built the clinical evidence base, the FDA regulatory track record, and the health system relationships that define category leadership. Today, Glytec and the unified GlytecOne platform serve 400+ hospitals and health systems nationwide, with Glucommander guiding safe insulin dosing for millions of patients, and Command Center providing the patient and systemwide visibility needed to support informed clinical and operational decisions.

To learn more, visit https://glytec.com/
LinkedIn: https://www.linkedin.com/company/glytec-llc/

Contact:
Matthew Mcpherson, Chief Financial Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.